Internal link ProQR Announces Year End 2024 Operating and Financial Results March 13, 2025 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets December 08, 2023 at 12:30 PM UTC
Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results November 07, 2023 at 12:00 PM UTC
Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing November 06, 2023 at 12:00 PM UTC
Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference September 28, 2023 at 12:00 PM UTC
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets September 27, 2023 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference September 07, 2023 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results August 03, 2023 at 11:00 AM UTC
Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets August 01, 2023 at 11:00 AM UTC
Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit July 06, 2023 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2023 Operating and Financial Results May 16, 2023 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 May 09, 2023 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in April and May April 20, 2023 at 12:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 April 18, 2023 at 12:00 PM UTC
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event March 29, 2023 at 12:00 PM UTC
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing March 14, 2023 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific and Industry Conferences March 07, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 February 28, 2023 at 01:00 PM UTC
Internal link ProQR Announces R&D Day and Provides Update on Innovation Portfolio November 30, 2015 at 12:00 PM UTC
Internal link ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials November 23, 2015 at 11:30 AM UTC
Internal link ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences October 01, 2015 at 11:00 AM UTC
Internal link ProQR to Present at the Leerink Partners 4th Annual Rare Disease Roundtable September 23, 2015 at 11:00 AM UTC
Internal link ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment September 14, 2015 at 11:00 AM UTC
Internal link ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients June 26, 2015 at 11:54 AM UTC